Abstract: An object of the present invention is to provide an asenapine-containing patch having excellent adhesiveness and handleability, which can persistently provide sufficient medicinal effects by suppressing cold flow during storage or application while enhancing skin permeability using a silicone-based pressure-sensitive adhesive base, and thereby maintaining the stability of the drug in the patch during storage, and maintaining an appropriate administration form for a long period of time. The present invention relates to a patch having a support and a pressure-sensitive adhesive layer, wherein the pressure-sensitive adhesive layer comprises asenapine and a silicone-based pressure-sensitive adhesive base, and the loss tangent (tan ?) of the pressure-sensitive adhesive layer is 0.75 to 1.5 at 1.0 Hz.

Abstract: Disclosed herein are several embodiments of a negative pressure appliance and methods of using the same in the treatment of wounds. Some embodiments are directed towards wound dressings comprising a liquid and gas permeable transmission layer, an absorbent layer for absorbing wound exudate, the absorbent layer overlying the transmission layer, a gas impermeable cover layer overlying the absorbent layer and comprising a first orifice, wherein the cover layer is moisture vapor permeable. Some embodiments are directed to improved fluidic connectors or suction adapters for connecting to a wound site, for example using softer, kink-free conformable suction adapters.

Abstract: In one embodiment, an adhesive support garment includes a base anchoring portion and a shaping panel. The base anchoring portion is configured to be adhered to a body beneath a breast. The shaping panel includes a fabric layer and an adhesive layer that is configured to extend from the base anchoring portion over the breast and adhere thereto. The shaping panel is configured to hold and orient the breast.

Abstract: The present disclosure relates to a method for providing a film. The method may include providing a base layer that is one or more of water resistant or oxygen resistant, coextruding a layer that may include a tie layer and a contact layer to provide a coextrusion layer, coating the coextrusion layer to the base layer, and allowing the coextrusion layer coated to the base layer to adhere to provide the film that may include the tie layer and the contact layer formed as a coextrusion layer coated to the base layer, wherein the tie layer may include at least one layer; and wherein the contact layer may include a polymer having a RED value based on a Hansen's Solubility parameter (HSP) towards an aggressive chemical of greater than 0.8.

Abstract: A montmorillonite slurry, containing a lithium-immobilized montmorillonite having a cation exchange capacity of 50 meq/100 g or less, ammonia, water, and an organic solvent, in which the organic solvent includes at least one kind of organic solvent selected from the group consisting of acetonitrile and methyl ethyl ketone, the proportion occupied by the organic solvent in the total amount of the water and the organic solvent in the slurry is 10% by mass or more and 90% by mass or less, and the content of ammonia in the slurry is 0.1 mmol or more per gram of the lithium-immobilized montmorillonite in the slurry; a method of producing the same; and a clay film.

Abstract: The present invention addresses the problem of providing a block copolymer which is useful as a surface treatment agent for cell culture substrates, said surface treatment agent enabling cell separation in a short period of time. The above-mentioned problem is solved by a block copolymer that includes the following blocks (A), (B) and (C): (A) a temperature-responsive polymer block that has a lower critical solution temperature (LCST) within the range of from 0° C. to 50° C. with respect to water (B) a hydrophilic polymer block that does not have an LCST within the range of from 0° C. to 50° C., while having an HLB value within the range of from 9 (inclusive) to 20 (exclusive) (C) a hydrophobic polymer block that does not have an LCST within the range of from 0° C. to 50° C., while having an HLB value within the range of from 0 (inclusive) to 9 (exclusive).

Abstract: A patch comprises a backing layer and an adhesive layer, wherein the adhesive layer contains at least one selected from the group consisting of butorphanol and pharmaceutically acceptable salts thereof, and contains an adhesive base and an antioxidant containing a sulfur atom in its molecule.

Abstract: A wound dressing comprises a wound pad and a backing layer on a non-wound facing side of the backing layer. At least a portion of a sealing ring is provided within 5 mm of and continuously along the contour of the wound pad. A negative pressure wound treatment system comprising such a wound dressing is also disclosed.

Abstract: A glove with thinner and thicker parts is disclosed. The thinner parts, in one version of the glove, cover all of a thumb and index finger and a distal phalanx of a middle and ring finger. The rest of the glove, in such an embodiment, is thicker. The thicker parts can include the palm and dorsal side of the hand. The thinner region palmar side of the distal phalanx of the middle and ring finger include, in embodiments of the disclosed technology, a pad with a peelable cover which reveals a local anesthetic and disinfectant. Such pads can further be used/attached with a version of the glove with only thinner material throughout. In this manner, one can grasp with greater dexterity with the thinner regions of the glove compared to the thicker regions and also use a disinfectant followed by an anesthetic.

Abstract: Adhesive compositions and patches, and associated systems, kits, and methods, are generally described. Certain of the adhesive compositions and patches can be used to treat tissues (e.g., in hemostatic or other tissue treatment applications), according to certain embodiments.

Abstract: Pharmaceutical formulations and methods useful for the treatment of anorexia and the stimulation of appetite and weight gain, and the management of weight loss in dogs and cats.

Abstract: The present invention relates to a medical nonwoven fabric comprising gelable cellulose derivative short-cut fibers as prepared by the paper making process, a preparation method thereof, and an adhesion prevention barrier using the same. The present invention provides a single phase of medical nonwoven fabric comprising gelable cellulose derivative short-cut fibers, to induce capillary action of micropores formed between the fibers and thereby control the gelation time, and provides a composite nonwoven fabric formed by laminating a nonwoven fabric layer comprising a different kind of biodegradable polymer material not susceptible to gelation on the single-phase of medical nonwoven fabric comprising gelable cellulose derivative short-cut fibers, thereby improving dimensional stability and convenience of surgical procedure. The present invention further provides a dyed medical nonwoven fabric to improve visibility, allowing easiness of recognizing the placement or location of the medical nonwoven fabric.

Abstract: Described are pressure-sensitive adhesive polymers (PSAs) useful, for example, for application to the skin, such as in the field of transdermal drug delivery. The PSAs include polar groups modeled on one or more polar portions of skin lipids, which contribute to good skin adhesion properties. Methods of making the PSAs, compositions comprising them, and methods of making and using them also are provided.

Abstract: Methods of producing a transdermal delivery patches are described comprising the preparation of a uniform suspension of drug particles. A plasticizer is added to the suspension. A solution of an adhesive is add to the suspension to form a drug suspension in the adhesive mixture. The drug suspension is coated on a release liner and all solvents are evaporated to form a solid drug reservoir layer. A medical device for transdermal administration of a drug can include the solid drug reservoir layer. Suitable drugs include fentanyl and sufentanil.

Abstract: The present invention relates to a method for stabilizing rotigotine, the method comprising providing a solid dispersion comprising polyvinylpyrrolidone and a non-crystalline form of rotigotine, wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6. The present invention also relates to a solid dispersion comprising a dispersing agent and a dispersed phase, said dispersed phase comprising rotigotine and polyvinylpyrrolidone, wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6, a pharmaceutical composition comprising such a solid dispersion, in particular a transdermal therapeutic system, as well as a method for the preparation thereof.

Abstract: The present invention relates to a method for stabilizing rotigotine, the method comprising providing a solid dispersion comprising polyvinylpyrrolidone and a non-crystalline form of rotigotine, wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6. The present invention also relates to a solid dispersion comprising a dispersing agent and a dispersed phase, said dispersed phase comprising rotigotine and polyvinylpyrrolidone, wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6, a pharmaceutical composition comprising such a solid dispersion, in particular a transdermal therapeutic system, as well as a method for the preparation thereof.

Abstract: A transdermal drug delivery system is provided that includes a drug-in-adhesive matrix layer and a backing layer. The matrix layer includes an active pharmaceutical ingredient, a cross-linked polyvinylpyrrolidone binder, a mesoporous silicon dioxide filler, and a pressure sensitive adhesive, while the backing layer forms an exterior facing-surface of the delivery system. The ratio of the mesoporous silicon dioxide filler to the cross-linked polyvinylpyrrolidone binder ranges from about 1:1 to about 1:8. As a result of the specific components of the matrix layer and the amounts in which they are utilized, the resulting delivery system, which can include a homogeneous dispersion of the active pharmaceutical ingredient in the formulation, is capable of delivering the active pharmaceutical ingredient over a period of up to about 7 days in a generally constant and controlled fashion. Further, the only layer that contemplates the use of an adhesive component is the drug-in-adhesive matrix layer.

Abstract: A module producible inside a living body is provided. The module includes an instructions receiver configured to receive wireless transmissions of instructions from a master controller located outside of the body when the module is inside the body. An energy receiver configured to receive wireless transmission of non-destructive energy from the master controller located outside of the body when the module is inside the body. The module further includes a battery and a communications and guide element electrically connected to the instructions receiver, the energy receiver and the battery.

Abstract: A disposable diaper includes: a first inflected unit formed in an absorber and extending along a product widthwise direction; a second inflected unit formed in the absorber, extending along the product widthwise direction, and positioned towards a rear waistline unit from the first inflected unit; and a crotch unit formed between the first inflected unit and the second inflected unit. The size of the crotch unit along the product longitudinal direction is 30 mm or more and 150 mm or less in the natural state of the disposable diaper.

Abstract: The present invention provides a hemostatic composite sponge comprising a porous matrix of a biomaterial and a bioadhesive material stably associated with said sponge and present in an organized pattern on said sponge.

Abstract: The invention discloses a gastric resistant pharmaceutical or nutraceutical composition, comprising a core, comprising a pharmaceutical or nutraceutical active ingredient and a gastric resistant coating layer onto the core, wherein the gastric resistant coating layer comprises at least 30% by weight of a (meth)acrylate copolymer comprising polymerized units of 10 to 40% by weight of acrylic or methacrylic acid, 10 to 80% by weight of a C4- to C18-alkyl ester of acrylic or methacrylic acid and optionally 0 to 60% by weight of another vinylic monomer, whereby the release of the pharmaceutical or nutraceutical active ingredient is not more than 10% under in-vitro conditions at pH 1.2 after 2 hours in medium according to USP with and without the addition of 20% (v/v) ethanol.

Abstract: According to aspects illustrated herein, there is provided an agent that transiently disrupts claudin-1 within tight junctions. The agent includes a peptide having at least 40% polar, uncharged amino acid residues and a self-assembled ?-sheet secondary structure. According to aspects illustrated herein, there is also provided a transepithelial drug and vaccine formulations, as well as isolated peptides, pharmaceutical compositions, and transdermal delivery devices. Also described herein are methods of disrupting epithelial barrier and methods of administering the transepithelial formulations described herein.

Abstract: Described are transdermal drug delivery systems for the transdermal administration of estrogen, comprising a polymer matrix and estrogen. Methods of making and using such systems also are described.

Abstract: Described are transdermal drug delivery systems for the transdermal administration of estrogen, comprising a polymer matrix and estrogen. Methods of making and using such systems also are described.

Abstract: The present invention relates to a pharmaceutical composition in the form of a hydro-alcoholic gel or a solution for transdermal application, comprising: from about 0.2% to about 1.5% of dihydrotestosterone; and from about 0.2 to about 3% of isopropyl myristate.

Abstract: Wearable patches comprising multiple separable adhesive layers. One or more of the layers can comprise electronics, mechanical components, gauze, medicine and/or other types of hardware suitable for the intended use of the patch. In use, a first layer of the patch is adhered to a user. When it is time to change layers, the patch is removed from the user, the first layer is removed from the patch to expose a second adhesive layer, and the second layer is applied to the user. The process may be repeated until the remaining layers of the patch have been used.

Abstract: The invention relates to a molded body, especially for parts, top shells, inner elements, accessories and components of devices, for molding materials, filling materials for medical technical devices and/or medical products. The inventive molded body is characterized by being in at least some sections germ-repellant. The invention also relates to a medical device which comprises at least one molded body according to the invention. The invention finally relates to a method for producing the inventive molded body.

Abstract: Light-activated antimicrobial devices and articles are disclosed. The devices include a light source and a light-activated antimicrobial article comprising a photosensitizer and a viscoelastic material such as a pressure sensitive adhesive adapted to receive light from the light source. The viscoelastic material may be adapted to transport light by total internal reflection. The photosensitizer may comprise a dye, a metal oxide or a composition that comprises anions that oxidize or react to form a gas. Upon activation of the light source, the photosensitizer absorbs light from the light source such that antimicrobial activity is exhibited. The photosensitizer may be included in the light-activated antimicrobial article or it may be provided as a topical composition that is separate from the article. The light-activated antimicrobial articles and devices may have constructions similar to those of wound dressings.

Abstract: The present invention is directed to a reinforced absorbable multilayered hemostatic wound dressing comprising a first absorbable nonwoven fabric, a second absorbable woven or knitted fabric, thrombin and/or fibrinogen.

Abstract: The present invention provides a patch package structure, which includes: a package including a first sheet material which is planar and a second sheet material which has been molded, the first and second sheet materials being sealed together in peripheral parts thereof, and a patch disposed in the package, in which the patch contains a backing, a pressure-sensitive adhesive layer laminated on at least one side of the backing, and a release liner which protects a pressure-sensitive adhesive surface of the pressure-sensitive adhesive layer; the second sheet material has been molded so as to have a protrudent part in at least a substantially central area thereof, the protrudent part having a planar outer shape larger than a planar outer shape of the release liner and having at least one recessed part; d is not smaller than T, in which d is the minimum gap distance between the inner surface of the first sheet material and the inner surface of the second sheet material at the recessed part and T is a thickness of

Abstract: The present invention provides a patch preparation that has an extremely low moisture permeability, has a sufficient ODT effect, is excellent in drug releasability, and has a preferred handleability. The patch preparation of the present invention includes a support; and a pressure-sensitive adhesive layer containing an adherent polymer and a drug on one surface of the support, wherein: the support has a polyester base layer, an inorganic oxide layer, and a polyester nonwoven fabric layer in the stated order; the polyester base layer has a thickness of 1.0 ?m to 16 ?m; and the pressure-sensitive adhesive layer is laminated on the polyester base layer.

Abstract: An adhesive dressing that reduces the leakage of wound exudate from the dressing, comprising an adhesive-coated backing sheet; and an absorbent island adhered to said adhesive-coated backing sheet by said adhesive, having a first end and a second end, wherein the absorption capacity of the absorbent island is higher at the first end than at the second end. The adhesive dressing of the invention provides extended wear time for the dressing when it is applied to wounds.

Abstract: A wound dressing is provided which includes an inner layer with a plurality of drain holes around the perimeter. The inner layer is resistant to penetration by liquid. Adjacent the inner layer is an absorbent layer. An outer layer is adjacent, but not attached to the absorbent layer. The outer layer is resistant to penetration by liquid. The outer layer includes an adhesive band. A removable protective layer covers the adhesive bands and includes a plurality of perforations spaced about the protective layer with a plurality of non-perforated sections between the perforations such that when removed, the perforations cause separation at the perforations and only one non-perforated section is removed at a time. A base layer is provided with an open area and adhesive bands. The base layer is attached to the skin and the outer layer covers the open area of the base layer.

Abstract: An apparatus and system for treating a wound having a cavity is disclosed. The apparatus comprises a scaffold including a scaffold lamina and a tissue lamina wherein the scaffold lamina forms a laminate in fluid communication with the tissue lamina. The laminate is rolled into a generally cylindrical shape having two end surfaces. The apparatus further comprises a manifold having a port for coupling to a source of reduced pressure and that is positioned in fluid communication with the scaffold to provide reduced pressure to the scaffold lamina and the wound. The apparatus also comprises a drape formed of substantially impermeable material to cover the scaffold and the manifold within the wound.

Abstract: Embodiments of method of manufacturing an implantable pump, including providing an upper layer comprising a dome structure for housing a drug chamber and a cannula in fluid communication with the drug chamber, providing a middle deflection layer adjacent the drug chamber, providing a bottom layer comprising electrolysis electrodes, and bonding the upper layer, middle deflection layer, and bottom layer to form the pump.

Abstract: Apparatuses to be worn by users proximate their ankles to manage pressure and swelling, the apparatus including a wrap shaped to conform to a portion of a foot and a lower leg of the user. In some examples, the wrap defines a compressible multiple layer construction including at least one layer that including a compressible foam, a channel sized to receive a portion of the foot and the lower leg, a substantially stretchable flap sized to extend across the channel when the foot and the lower leg are positioned within the channel, a leg portion, and a foot portion, wherein the leg portion may be flexibly angled from the foot portion a bandaged area including the user's ankles. In some examples, the wrap is configured to be fitted around a portion of the user's foot and lower leg to compress at the ankle area to a selected barrier pressure.

Abstract: The purpose is to provide a mirtazapine-containing transdermal patch capable of suppressing deposition of a crystalline component derived from mirtazapine, deterioration in sense of use, and deterioration in adhesiveness to the skin. The transdermal patch contains a support, a drug-containing layer and a release liner, and the drug-containing layer contains mirtazapine and an organic acid.

Abstract: The invention relates to a pharmaceutical patch for transdermal administration of the pharmacologically active ingredient Tapentadol or a physiologically acceptable salt thereof, the patch comprising a surface layer, an adhesive layer which comprises a pressure sensitive adhesive and at least a portion of the total amount of the pharmacologically active ingredient that is contained in the pharmaceutical patch, and a removable protective layer, wherein the adhesive layer is located between the surface layer and the removable protective layer.

Abstract: Compositions for the transdermal delivery of amphetamine in a flexible, finite form are described. The compositions comprise a polymer matrix that includes amphetamine or a pharmaceutically acceptable salt or prodrug thereof and a backing layer comprising a polyurethane film layer and a polyester film layer, with a polyurethane adhesive disposed therebetween. Related methods also are described.

Abstract: The present invention refers to a transdermal delivery device comprising a backing layer, at least one adhesive layer, and a release liner coated with a UV-cured highly crosslinked silicone. The present invention also refers to a method of preparing a transdermal delivery device comprising a backing layer, at least one adhesive layer, and a release liner coated with a UV-cured silicone.

Abstract: A composite wound dressing and delivery apparatus includes a substantially transparent dressing layer having a lower surface that is coated with a pressure sensitive for applying the dressing layer over a wound to define a reservoir in which a negative pressure may be maintained. A substantially transparent backing layer adhered to the lower surface of the dressing layer in a releasable manner, and a vacuum port is centrally located on the dressing layer. The vacuum port is adapted to provide fluid communication between a vacuum source and the reservoir through the dressing layer. A targeting grid associated with either the dressing layer or the backing layer includes regularly spaced reference marks along at least two axes extending from the vacuum port.

Abstract: Described are transdermal drug delivery compositions comprising amphetamine, methods of manufacturing transdermal drug delivery compositions comprising amphetamine, and therapeutic methods using transdermal drug delivery compositions comprising amphetamine, such as may be desired for achieving central nervous system stimulation, such as for the treatment of attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), or for the treatment of narcolepsy. In some embodiments, the compositions comprise an amount of polyurethane effective to control the presence of and/or prevent the formation of phenyl acetone in the compositions. The polyurethane may be present in a drug-containing polymer matrix or in a backing adjacent the drug-containing polymer matrix.

Abstract: The invention is intended to provide an adhesive patch which contains a drug except bisoprolol and which effectively inhibits the occurrence of oozing out or sticking out of the adhesive layer components from the exposed area of the adhesive layer of the adhesive patch during storage as well as the occurrence of oozing out of the drug from the adhesive layer thereby preventing the reduction in drug content. The support, the release liner and the adhesive layer constituting the adhesive patch each are formed to have a rectangular planar shape and the entire adhesive patch are formed to have a rectangular planar shape, and a protrudent part is formed on the support-side surface of the adhesive patch at a corner thereof. In addition, the adhesive patch may be formed to have a middle part and a peripheral part, and the protrudent part may be formed at a corner of the rectangular middle part.

Abstract: The present invention relates to a bandage including an adhesive hydrocolloid mass, wherein said bandage includes, on at least one portion of the surface of the adhesive mass intended for being in contract with the wound when the bandage is being used, a plurality of agglomerates made up of particles linked to one another, preferably in a multi-layer configuration, at least 90% and preferably at least 95% of said particles being made up of one (or more) material(s) selected among polysaccharides, proteins and synthetic polymers, and being suitable for solubilizing or gelling in under ten seconds, and preferably still in less than one second when in contact with the exudate from the wound. The bandage according to the invention is intended for treating wounds such as blisters, exuding wounds, burns and dermal-epidermal lesions, whether superficial, deep, chronic or acute.

Abstract: A bandage and method for securing a tension member comprising a central body and a plurality of tabs disposed about the central body. A tension member may be disposed across or through a slit or aperture of the central body. A body adhesive on the lower surface of the central body may secure the bandage to the patient. The tension member may then be pulled across the upper surface of the central body and a first tab may be folded over and adhered to the tension member and central body. The tension member may then be pulled back across the first tab and a second tab may be folded over and adhered to the tension member and first tab. Likewise, the tension member may then be pulled back across the second tab and a third tab may be folded over and adhered to the tension member and second tab.

Abstract: Disclosed is a transdermal patch for treatment of degenerative neurological disorders like dementia or Alzheimer type dementia. More particularly, the transdermal patch for treatment of neurodegenerative disorder comprises an adhesive monolayer which comprises Rivastigmine in free base form or its pharmaceutically acceptable salts, styrene block copolymer, and a tackifier, wherein total styrene units are in an amount of 4% w/w or more of said adhesive monolayer.

Abstract: Provided is a transdermal delivery system (for example, in the form of a patch) having a double-layer structure including a drug-containing matrix layer and an adhesive layer, wherein the drug-containing matrix layer is obtained by completely dissolving donepezil using a certain polymer and then formulating along with an adhesive; and a process for preparing the same. The transdermal delivery system according to the present invention does not show any crystallization of donepezil in the formulation, can release donepezil at a uniform rate for a long time, and can inhibit the release dumping phenomenon that occurs in a transdermal delivery system having a single-layer structure.

Abstract: The present invention relates to a transdermal device including porous microparticles capable of containing an active principle, in particular nicotine, and to the use thereof as a drug, in particular for tobacco cessation. The present invention further relates to a method for preparing a transdermal device including porous microparticles filled with an active principle.

Abstract: A device for use with a negative pressure bandage for supply negative pressure. The device includes a pump module and a controller module. The pump module contains a power source and a pump. The pump module is removably contained in the controller module. The pump module and controller module can be connected with a connector that provides both a physical and pneumatic connection. The controller module may include one of more visual indicators for allowing the status of the device to be observed at a distance.

Abstract: A wound dressing, a method of manufacturing a wound dressing, and a method of treating a patient are disclosed. The wound dressing may include an absorbent layer for absorbing wound exudate; and an obscuring element for at least partially obscuring a view of wound exudate absorbed by the absorbent layer in use.